Search PubMed⌕ Search

Biomedical subjects

A McMican

Publications and source records attributed to A McMican.

11 recordsLinked to original sources
PubMed1987

Comparison of monoclonal antisera with conventional antisera for Lewis blood group antigen determination.

Monoclonal blood grouping sera provide a means of overcoming difficulties inherent in the use of conventional polyclonal reagents. Two murine monoclonal anti-Lewis reagents were tested and found to be comparable to conventional reagents for use in red cell phenotyping. These reagents may detect Le(a) antigen on Le(a-b+) red cells with greater sensitivity than previously available polyclonal anti-Lewis reagents.

Antibodies, Monoclonal↗
PubMed1983

Rh sensitization.

Explore the source record for details and available documents.

Cost-Benefit Analysis↗
PubMed1982

A new approach to washing red blood cells frozen with a high concentration of glycerol in a special freezing container.

We report here on a new approach to washing red blood cells frozen with a high concentration of glycerol in a special freezing container. The wash solution consists of a 150-ml volume of 12% sodium chloride and 2 liters of 0.9% sodium chloride-0.2% glucose-25 mEq/l disodium phosphate. Both the Haemonetics Blood Processor 115 and the IBM Blood Processor 2991 have been used with this protocol, with similar results. The in vitro recovery of red blood cells frozen with 8.6M glycerol was 89%, and that of red blood cells frozen with 6.2M glycerol was 93%. The 24-hour posttransfusion survival values averaged 88% for eight units of outdated-rejuvenated previously frozen red blood cells washed by this protocol and stored at 4 degrees C for 3 days before autotransfusion.

Blood Preservation↗
PubMed1981

Plateletpheresis experience with the Haemonetics Blood Processor 30, the IBM Blood Processor 2997, and the Fenwal CS-3000 Blood Processor.

Comparisons were made of the apheresis instruments Haemonetics Blood Processor 30, IBM Blood Processor 2997 and Fenwal CS-3000, for collection of platelets from normal donors. With each instrument the mean recovery was at least 4 x 10(11) platelets per procedure, and each instrument afforded a safe and reliable collection. The Haemonetics Blood Processor gave the lowest recovery of platelets per minute per procedure. The IBM Blood Processor 2997 required the longest time for set-up and priming and processed 1.5 liters more donor blood per collection than the other instruments. The Fenwal CS-3000, which is a computer-controlled instrument, was the least time consuming. The donor suffered a significantly greater drop in platelet count after collection with the IBM Blood Processor 2997 (31%) than after collection with the other instruments (19%), and we were unable to account for this observation.

Blood Platelets↗
PubMedDate not supplied

Survival of MM red cells during hypothermia in two patients with anti-M.

The in vivo survival of M(M+N-) red cells in two patients with anti-M was studied during hypothermia. The antibodies were IgM, of low titer, and did not react at 30 degrees C. 51Cr survival studies were performed using 2 ml of labeled blood. There was normal circulation of M(M+N-) cells at 37 degrees C and no accelerated loss of these cells at blood temperatures between 16 and 28 degrees C. One patient received 187 ml of MN (M+N +) red cells when the blood temperature was 25 degrees C without evidence of clinical transfusion reactions and without development of positive direct anti-human globulin test. Hypothermia did not adversely affect the immediate survival of M(M+N-) red cells transfused to patients with anti-M antibodies reactive in vitro below 30 degrees C.

Aged↗
PubMedDate not supplied

A critical survey of fresh-frozen plasma use.

The use of 534 units of fresh-frozen plasma (FFP) during 160 transfusion episodes in 135 consecutive patients was reviewed. Only 27 percent of transfusions were indicated by a need for replacement of labile coagulation factors. Other uses included volume repletion (31%), intraoperative bleeding or massive transfusion without coagulopathy (19%), and miscellaneous indications unrelated to labile coagulation factors (23%). Data from other institutions and national sources support the hypothesis that much of the increase in FFP use over the last decade is related to decreases in whole blood availability rather than to use for labile coagulation factor replacement. The use of FFP and red cells as a substitute for, or in preference to, whole blood may have significant adverse implications in terms of the cost and safety of blood transfusion.

Blood Coagulation Disorders↗
PubMedDate not supplied

Life-threatening autoimmune hemolytic anemia in a patient with the acquired immune deficiency syndrome.

Increasing numbers of patients are being seen with the acquired immune deficiency syndrome (AIDS). An abnormal serology with a positive direct antiglobulin test has been observed in these patients and is usually not thought to contribute to significant clinical morbidity. We describe a patient with AIDS who presented with a severe hemolytic anemia which was not distinguishable clinically and serologically from the idiopathic form of autoimmune hemolytic anemia.

Acquired Immunodeficiency Syndrome↗